Compare Garmin Ltd. (GRMN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs TG Therapeutics Inc — how do they compare? Garmin Ltd. trades at $309.51 (market cap $59.72B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Garmin Ltd. is far larger — about 7.8× TG Therapeutics Inc's market cap, and Garmin Ltd. pays a 1.36% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GRMN | TGTX | |
|---|---|---|
Market Cap | $59.72B | $7.64B |
Sector | Technology | Health |
52-Week High | $313.16 | $59.06 |
52-Week Low | $187.10 | $26.94 |
Enterprise Value | $57.23B | $7.84B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $310.07, near its all-time high, with a slight daily decline of 0.99%. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing estimates of $2.30, and raised full-year guidance. Revenue growth remains robust, supported by strength in the fitness segment, while profitability metrics like a 60.08% gross margin highlight operational efficiency.
The outlook for GRMN is positive, driven by sustained demand in wearables and fitness technology, but risks include rich valuation multiples and potential growth deceleration. Analyst consensus is a 'Hold' with a $318.67 price target, suggesting limited near-term upside. Investors should weigh strong execution against premium pricing and competitive pressures in the consumer hardware space.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
